Timocar

Quick links to important sections

Timocar

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Timocar

Quick Facts

Property Description
Active ingredient Timolol maleate
Form Ophthalmic solution (Eye drops)
Pharmacological class Non-selective Beta-blocker
General purpose Ocular hypotensive action
Origin Synthetic

Timocar: Classification and Core Composition

Timocar is a prescription-only synthetic medicinal product formulated as a topical ophthalmic solution containing the active substance Timolol maleate. This drug is formally classified as a non-selective beta-adrenergic receptor blocking agent, a pharmacological category commonly known as a beta-blocker. This designation places the product among established agents utilized in clinical practice for its precise modulatory effect on adrenergic signals in the eye.

The product is a single-ingredient solution; its therapeutic effect is derived exclusively from the action of Timolol. The specific composition ensures the product meets the stringent requirements for sterile ophthalmic preparations, providing stable and effective delivery of the active substance for local action within the eye structures.


Form and Application Type

Timocar is supplied as a sterile, water-based, clear liquid preparation specifically engineered for its topical ocular route of administration, applied directly as eye drops. The formulation is a buffered aqueous solution, ensuring it is isotonic and pH-balanced to maintain patient tolerance during application.

This choice of a liquid solution is critical for local absorption, allowing the active component to target internal ocular structures efficiently, which is necessary for the drug’s general therapeutic function. Timolol maleate is readily incorporated into an aqueous vehicle for precise ophthalmic delivery.


General Therapeutic Purpose and Action

The fundamental general purpose of Timocar is to deliver a reliable ocular hypotensive action, a benefit clinically recognized for its efficacy in maintaining internal eye pressure within a stable range. This foundational benefit is achieved by the active component’s mechanism of non-selective blockade of specific adrenergic receptors located in the ciliary body.

By inhibiting the signals that stimulate the production of aqueous humor, the drug helps sustain stable, lowered intraocular pressure. This ability to consistently regulate fluid balance distinguishes the beta-blocker class of ophthalmic agents and constitutes the product’s overarching therapeutic benefit.

What side effects are possible with Timocar?

Timocar (Timolol maleate ophthalmic solution) is associated with potential adverse reactions that are classified based on both local ocular effects and the systemic effects of its beta-adrenergic blocking component, which is absorbed systemically following topical application. The safety profile is organized by regulatory authorities into frequency and affected body systems.

Adverse Reaction Scope

Adverse reactions are officially classified by incidence. Common effects, reported in up to 10% of patients, include local ocular irritation, burning, stinging, and headache. Uncommon effects may involve dizziness and depression. Rare effects include systemic reactions such as cardiac arrhythmia, syncope, and bronchospasm, documented at incidences below 0.1%

.

System-Organ Classes affected include Eye Disorders (e.g., blurred vision, dry eyes), Cardiac Disorders (e.g., bradycardia), Respiratory Disorders (e.g., dyspnea), and Nervous System Disorders.

Safety Constraints and Serious Reactions

The label explicitly notes the potential for Serious Adverse Reactions, including Cardiac Arrest, Overt Cardiac Failure, and severe Bronchospasm, which reflect the systemic activity of the medicine. Due to this systemic absorption, the product is contraindicated in patients with pre-existing conditions such as bronchial asthma or severe chronic obstructive pulmonary disease, as well as specific cardiac conditions like sinus bradycardia and second or third-degree atrioventricular block.

Safety notes also indicate that ocular irritation may be more noticeable at the start of treatment, and a diminished therapeutic response may occur with long-term use.

Overdose and Emergency Response

The official regulatory profile for Timocar overdose centers on the risk of systemic beta-adrenergic blockade that may occur following excessive topical application or accidental ingestion. Documented overdose presentations include signs of cardiovascular depression, such as pronounced bradycardia (slow heart rate) and hypotension (low blood pressure). Severe outcomes that can be life-threatening include cardiac failure, protracted severe hypotension, and cardiac arrest. Population-specific notes require extreme caution in neonates and young children due to the risk of apnoea (cessation of breathing).

Regulators mandate that individuals seek immediate medical attention in the event of an overdose. Immediate emergency services must be contacted if the patient collapses, has a seizure, or is experiencing severe trouble breathing. The official documentation specifies that there is no specific antidote known for Timolol toxicity. Therefore, management is explicitly defined as symptomatic and supportive treatment. This includes procedural steps like considering gastric lavage if ingested and using specific pharmacological agents, such as Atropine sulfate for bradycardia, to counteract the systemic effects, as directed by medical guidance. Close monitoring is necessary due to the potential for severe, sustained effects.

Therapeutic Uses of Timocar

Timocar is relevant in contexts marked by increased discomfort or tension and is generally applied across domains where additional symptomatic support is needed. Medicines in this class are considered relevant for easing symptoms that may interfere with daily comfort. The medicine is commonly used across conditions presenting with acute episodes, is relevant in conditions characterized by periods of heightened symptoms, and is applied in situations involving recurrent or episodic manifestations.


Easing Symptom Fluctuation

This medicine helps address symptom clusters that may become intense or disruptive, such as when symptoms appear suddenly or fluctuate. It is often used when symptoms intensify and supportive relief is needed, providing support that helps ease the overall symptom burden. This supports general well-being during symptomatic phases, which may assist with maintaining a sense of stability when symptoms are more noticeable.


Key Therapeutic Applications

It is commonly used across conditions presenting with disruptive symptom manifestations and is applied during phases where the patient experiences heightened discomfort. It may assist with maintaining functional stability and is relevant when supportive symptom management is appropriate, such as in clinical settings that involve acute or unstable symptom patterns.

Quick Fact: Relief for Noticeable Physiological Strain

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Timocar — Official Regulatory Information

Timocar (Timolol maleate ophthalmic solution) is a beta-blocker, and regulatory eligibility is strictly defined by the potential for systemic absorption, which may affect the heart and lungs.


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults (ge 18 years of age). Children 2 years of age and older may use it, with the dose determined by a physician.
Populations for whom use is not recommended Pregnant individuals: Not recommended unless absolutely necessary. Breastfeeding individuals: Use is generally not recommended; requires discontinuation of the drug or nursing.
Populations for whom use is contraindicated Patients with bronchial asthma or a history of asthma, or severe chronic obstructive pulmonary disease (COPD). Patients with sinus bradycardia, second or third degree AV block, overt cardiac failure, or cardiogenic shock.
Age-related eligibility rules Use in children younger than 2 years of age is not established and not recommended due to potential systemic absorption and risk of apnea.
Condition-specific eligibility rules Patients with diabetes mellitus or mild to moderate COPD must use with caution. Patients with first-degree AV block also require caution.

Eligibility Classifications (High-Level)

Classification Details (as defined in official documents)
Absolute Contraindication: Asthma/Severe COPD, Overt Cardiac Failure, Severe Bradycardia/AV Block. Conditional Use/Caution: Mild/Moderate COPD, Diabetes, First-Degree AV Block. Not Recommended: Pregnancy, Lactation, Children < 2 years.

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use Timocar by classifying patient groups based on the systemic risk of the beta-blocker component. This results in absolute prohibitions for those with severe heart and lung diseases, and conditional use or non-recommended status for special populations and those with certain chronic conditions.

What should I know about interactions with other medicines?

The active substance in Timocar, Timolol maleate, can be systemically absorbed even after topical application, leading to officially documented interaction patterns primarily involving additive pharmacodynamic effects and pharmacokinetic inhibition.

Documented Interaction Classes

Classification Interacting Agents Official Interaction Outcome
Additive Systemic Beta-Blockade Systemic or other topical Beta-Adrenergic Blocking Agents Potentiation of overall systemic beta-blockade; co-administration is not recommended.
Additive Cardiovascular Effects Oral or intravenous Calcium Antagonists (e.g., verapamil, diltiazem); Catecholamine-Depleting Drugs (e.g., reserpine) Increased risk of atrioventricular conduction disturbances, left ventricular failure, hypotension, and marked bradycardia.
Metabolic/Exposure Alteration Strong CYP2D6 Inhibitors (e.g., quinidine, fluoxetine, paroxetine) Potentiated systemic beta-blockade, including reports of decreased heart rate.

Other Official Restrictions

  • Administration Constraints: When using multiple topical ophthalmic products, other medications should be administered at least 10 minutes before instilling the gel-forming Timocar solution.
  • Procedural Caution: Beta-blockade may augment the risk of general anesthesia in surgical procedures, with reports of protracted severe hypotension.
  • Population Notes: Timocar may mask the signs of acute hypoglycemia in diabetic patients and may also mask clinical signs of hyperthyroidism (thyrotoxicosis).

Mechanism of Action

Timocar (Timolol maleate) is a non-selective beta-blocker that acts by directly targeting the suppression of aqueous humor formation. Its mechanism involves a specific molecular cascade that adjusts local ocular fluid dynamics.

Timocar acts as an antagonist, binding to and blocking both the Beta-1 (beta1) and Beta-2 (mathbfbeta2) adrenergic receptors located primarily in the ciliary processes of the eye. This critical first step interrupts the sympathetic nervous system signal, preventing the binding of endogenous stimulating agents like norepinephrine and epinephrine and suppressing the molecular process that drives fluid secretion.

The blockade of the beta2 receptors leads to the inhibition of the cyclic AMP (cAMP) signaling cascade within the ciliary body's epithelial cells. By lowering the concentration of cAMP, the mechanism downregulates the ion transport necessary for active fluid secretion. The resulting reduction in the rate and volume of aqueous humor formation represents the core mechanism-driven adjustment of ocular fluid dynamics.

Crucially, the drug's primary action is the suppression of fluid input volume. Its mechanism is constrained by a lack of significant influence on the conventional aqueous humor outflow pathways (e.g., the trabecular meshwork). The mechanistic effect on Intraocular Pressure (IOP) is dependent on the suppression of input volume, rather than the enhancement of fluid removal.

Dosage and Administration Information

Administration Overview

Timocar is typically administered as an ophthalmic solution. Proper technique is essential to ensure the solution is applied effectively to the ocular surface.

Application Technique

To apply the eye drops, the head is usually tilted back slightly while the lower eyelid is gently pulled down to create a small pocket. The dropper tip is positioned above the eye without making direct contact with the eye, eyelids, or surrounding surfaces. After the drop is placed into the conjunctival sac, the eye should be closed gently.

Nasolacrimal Occlusion

To minimize systemic absorption of the medication, pressure can be applied to the nasolacrimal duct (the inner corner of the eye near the nose) for one to two minutes immediately after application. This helps keep the medication localized to the ocular area.

Use with Other Ophthalmic Medications

If more than one topical ophthalmic medication is being used, the applications should be spaced apart. A typical interval involves waiting several minutes between the administration of different types of eye drops to prevent the second drop from washing out the first.

Contact Lens Considerations

If contact lenses are worn, they are generally removed prior to the application of the solution. Depending on the specific formulation, a waiting period is often observed before reinserting the lenses.

Recent Clinical Evidence

Research evidence / Overview of studies for Timocar

Evidence for Use in Managing Elevated Intraocular Pressure

Research exploring Timocar was evaluated in Randomized Controlled Trials (RCTs) and systematic reviews, primarily including adults diagnosed with Ocular Hypertension or Primary Open-Angle Glaucoma—conditions marked by functional limitations related to pressure inside the eye. The central focus of these studies was the evaluation of changes in Intraocular Pressure (IOP), a primary endpoint in conditions associated with pressure inside the eye. Most initial assessments involved observing responses over defined time intervals, typically ranging from three to twelve months.

Studies report how IOP measurements evolved during the study period. Findings describe IOP patterns observed in the studied adult populations; these patterns contribute to the broader evidence landscape. However, follow-up durations were limited in many initial trials. Research provides context, but long-term outcomes related to disease progression are not fully established.


Comparative Trial Landscape

Research also explored Timocar's effects against other active prescription ophthalmic treatments. These trials were designed to examine how changes in the pressure inside the eye compared across different approaches. Findings were mixed in some instances, depending on which newer drug classes (such as prostaglandin analogues) were evaluated in comparison. Comparative evidence is lacking for some current treatment options, and data regarding newer combination therapies remain limited.


Evidence in Specific Populations and Uncertainties

The majority of the research has been conducted in a broad adult and older adult population. Separate research explored the use of Timocar in pediatric patients (children aged two years and older) who have elevated eye pressure. Data for certain groups, particularly children, remain insufficient compared to the adult data.

Key areas of uncertainty remain. Long-term effects are not fully established, particularly how sustained pressure changes relate to outcomes reflecting daily functioning over many years. In some older studies, sample sizes were modest, and subgroup findings regarding patients with complex concurrent health issues are uncertain. Studies help show what has been observed so far, but the evidence highlights what is known—and what is still uncertain.

Key Studies & References

  1. National Institute for Health and Care Excellence (NICE): Glaucoma: diagnosis and management (NG81) - Summary of evidence for pharmacological management

Frequently Asked Questions (FAQ)

Common questions about Timocar (FAQ)

Q: Is Timocar considered a blood pressure medicine?

Official documents classify this medicine as a beta-blocker. Because the drug can be absorbed systemically, it may cause systemic effects that are similar to those of oral beta-blockers, which can include changes in heart rate and blood pressure.


Q: Does Timocar make you feel tired or drowsy?

Official product information indicates that feeling tired or experiencing unusual weakness is a potential side effect. Other central nervous system effects, such as dizziness and somnolence (sleepiness), are also listed in the adverse reaction profiles.


Q: Is it necessary to take Timocar every day?

The drug is typically prescribed for regular, consistent use to manage the condition. Since the medicine works to control a chronic condition, sudden stopping of its use is not advised and may cause the underlying condition to worsen.


Q: Why do some people experience [Common side effect, e.g., dizziness] with Timocar?

Official regulatory warnings indicate that, due to absorption into the body, the medicine may cause systemic adverse effects. Dizziness and lightheadedness are reported effects listed in the product information.


Q: Can Timocar affect blood sugar levels?

Regulatory documents indicate this drug may affect blood sugar levels. A specific warning is noted that it can mask the common physical signs and symptoms of acute hypoglycemia (very low blood sugar).


Q: What is the purpose of the 'inactive ingredients' in Timocar tablets?

The product contains components beyond the active drug, known as inactive ingredients or excipients. These components do not have a therapeutic effect but are included in the formulation to ensure the product maintains its necessary physical characteristics and stability for proper use.


Q: Does taking Timocar cause changes in mood or sleep?

Changes in mood and sleep patterns are listed among the potential side effects of this medicine. Specifically, official documentation reports the potential for depression, nightmares, and trouble sleeping (insomnia).


Q: What does the term 'contraindication' mean regarding Timocar?

A contraindication is a critical warning in official documents defining a condition or circumstance in which the drug should absolutely not be used. It signifies that using the medication under these conditions is associated with risks that outweigh any potential benefit.


Q: Is it normal to have mild headaches when first starting Timocar?

Headaches are listed in the official adverse reaction reports as a common potential side effect of the medication.


Q: Why is Timocar sometimes combined with other medicines in treatment plans?

The drug may be used as part of a combination regimen when achieving the target eye pressure is not maintained by Timocar monotherapy (use alone). It may be used to enhance the pressure-lowering effect.


Q: Is it true that Timocar is only used for very severe conditions?

Official documents indicate this medicine is used for both ocular hypertension (elevated eye pressure) and chronic open-angle glaucoma. It is not exclusively indicated for the most severe stages of the disease, but for conditions marked by elevated intraocular pressure.


Q: Does Timocar contain any ingredients that might cause an allergic reaction?

Official guidance notes that the drug is contraindicated if a patient has known hypersensitivity to the active substance or to any of the inactive components (excipients) in the formulation. Allergic reactions, such as rash or swelling, are listed among the rare potential side effects.


Q: Can Timocar cause temporary vision changes?

The application of the ophthalmic solution may cause temporary vision changes. Regulatory documents specify that effects such as blurred vision can occur following administration.


Q: How quickly should I expect to notice any changes after starting Timocar?

Official information indicates that a reduction in eye pressure may be observed as soon as 20 minutes after administration. However, the full, stable pressure-lowering effect may require approximately four weeks to be accurately assessed.


Q: What happens if I miss a scheduled dose of Timocar?

Official patient information contains specific instructions for managing a missed dose. These instructions typically advise on when to administer the dose versus when to skip it to maintain the treatment schedule. The guidance specifies to skip the missed dose if it is near the next scheduled application time.


Q: Can Timocar affect how other common over-the-counter medicines work?

Official product labeling advises patients to disclose the use of all prescription, non-prescription (OTC) medicines, and supplements to their healthcare provider. This is because certain common over-the-counter products may interact with the systemic activity of the drug, due to potential interactions.


Q: Are there any specific foods or drinks I should avoid while using Timocar?

Regulatory guidance identifies an interaction with alcohol, noting that it may have additive effects in lowering blood pressure. There are generally no specific restrictions on solid foods while using the eye drop formulation.


Q: Is Timocar known to cause weight gain or loss?

Changes in body weight are listed as potential adverse effects in official reports. Both unusual weight gain (which may be a sign of a serious condition) and weight loss have been reported in the adverse reaction profile.


Q: Does Timocar interact with caffeine or alcohol?

Regulatory guidance notes that alcohol consumption may cause an additive effect that further lowers blood pressure. Official documents do not list specific warnings for caffeine.


Q: How long does the effect of one dose of Timocar typically last?

The drug's official profile indicates the effect is intended to last for a prolonged period, typically up to 24 hours per dose.


Q: What is the difference between the immediate-release and extended-release forms of Timocar?

The official documents describe different forms, primarily the standard solution and a gel-forming solution. The different formulations are primarily distinguished by their administration frequency.


Q: Does Timocar have a risk of dependence or withdrawal symptoms?

Regulatory warnings state that sudden discontinuation of the drug is not advised. This is because sudden stopping may cause the underlying eye pressure condition to worsen.


Q: Is Timocar available as a generic medicine?

The medicine is available in a generic version known by its active substance, Timolol maleate ophthalmic. Generic availability is determined by regulatory bodies after patent expiration.


Q: Are there specific times of day when Timocar is usually taken?

Official information indicates that if the drug is prescribed for use multiple times a day, consistent timing is suggested to maintain steady medication levels.


Q: Will Timocar interfere with my ability to drive or operate machinery?

Regulatory warnings note that the medicine can cause temporary blurred vision and dizziness. The official warning indicates that operating vehicles or complex machinery should be avoided until these effects have cleared.


Q: Is Timocar known to interact with herbal supplements like St. John's Wort?

Official guidance indicates that there is generally insufficient data available to confirm the safety of using herbal remedies or dietary supplements alongside this prescription medication. Official guidance emphasizes the need to disclose all herbal and dietary supplements to a healthcare provider.


Q: Can a person stop using Timocar suddenly?

Regulatory warnings state that sudden discontinuation of the drug is not advised. This is because sudden stopping may cause the underlying eye pressure condition to worsen.


Q: What is the average duration of treatment with Timocar?

Official sources describe this medicine as a control for a chronic condition, rather than a cure. Therefore, continued, long-term use is typically expected unless a doctor determines that the medication is no longer necessary.


Q: Is there a maximum daily amount of Timocar described in official documents?

Regulatory documents indicate that for the 0.5% strength, dosages exceeding one drop in the affected eye(s) twice daily are generally not expected to offer any further reduction in eye pressure. The maximum effective amount is determined based on the established clinical data.


Q: Are people with kidney problems generally eligible to use Timocar?

Official regulatory documents note that the drug is eliminated from the body via excretion, which involves the kidneys. Caution may be advised for patients with known renal (kidney) issues.


Q: What kind of monitoring (tests) is usually done when taking Timocar?

Official guidance suggests that the patient's intraocular pressure (IOP) should be re-evaluated after approximately four weeks to assess the full response to treatment. Additionally, heart rate and blood pressure may be monitored due to the systemic nature of the drug’s effects.


Q: Does Timocar affect my cholesterol levels?

Official reports note that this medication may cause changes in serum lipid (fat) profiles. These changes include a reported potential for a slight decrease in HDL-cholesterol and a slight increase in triglyceride levels.


Q: What does official guidance say about using Timocar with cold or flu medicines?

Official guidance notes the importance of disclosing all nonprescription cold or flu medicines. This is due to the potential for some over-the-counter ingredients to interact with the systemic effects of the drug.

How should Timocar be stored and disposed of?

How to Store and Dispose of Timocar

Timocar (timolol maleate ophthalmic solution) must be stored under specific environmental and handling conditions defined in regulatory labeling to maintain stability and sterility.

Storage Requirements

The medicine requires storage at controlled room temperature, specifically between 15 C and 25 C (59 F and 77 F). The product must be protected from light and must not be frozen.

Condition Requirement
Temperature 15 C to 25 C
Protection Protect from light; Do not freeze
Container Keep in original container; keep tightly closed
Child Safety Keep out of reach of children

Stability and Disposal

To prevent contamination, users must avoid touching the dispenser tip. Multi-dose containers must be discarded 28 days after first opening. Unit-dose vials must be thrown away immediately after a single use. Disposal of any unused or expired product must be carried out in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Timocar found in:

A-Z Index: